Neurology:多发性硬化疾病活动 与GCIP厚度加速减退相关

2013-01-09 Neurology CMT 程蓓 编译

  一项美国和加拿大联合研究显示,伴临床和(或)影像学非眼部病变活动征象的多发性硬化症(MS)患者(尤其是在病程早期),其神经节细胞/内丛状层(GCIP)厚度呈加速减退趋势。论文发表于《神经病学》[Neurology 2013,80(1):47]杂志。   研究者对于MS组(n=164)和健康对照组(n=59)每6个月进行一次频域光学相干断层成像扫描,在基线和每年度实施增强脑部磁共振检

  一项美国和加拿大联合研究显示,伴临床和(或)影像学非眼部病变活动征象的多发性硬化症(MS)患者(尤其是在病程早期),其神经节细胞/内丛状层(GCIP)厚度呈加速减退趋势。论文发表于《神经病学》[Neurology 2013,80(1):47]杂志。

  研究者对于MS组(n=164)和健康对照组(n=59)每6个月进行一次频域光学相干断层成像扫描,在基线和每年度实施增强脑部磁共振检查。结果显示,在随访期间,出现残疾进展患者的年度GCIP厚度减退增快37%;与病程>5年者相比,病程<5年者的年度GCIP厚度减退增快43%(P=0.003)。同时伴有新发钆增强病变、新发T2病变和病程<5年三种特征患者的年度GCIP厚度减退率最高(P<0.001)。


Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning

Objective: To determine the effect of clinical and radiologic disease activity on the rate of thinning of the ganglion cell/inner plexiform (GCIP) layer and the retinal nerve fiber layer in patients with multiple sclerosis (MS) using optical coherence tomography (OCT).

Methods: One hundred sixty-four patients with MS and 59 healthy controls underwent spectral-domain OCT scans every 6 months for a mean follow-up period of 21.1 months. Baseline and annual contrast-enhanced brain MRIs were performed. Patients who developed optic neuritis during follow-up were excluded from analysis.

Results: Patients with the following features of disease activity during follow-up had faster rates of annualized GCIP thinning: relapses (42% faster, p = 0.007), new gadolinium-enhancing lesions (54% faster, p < 0.001), and new T2 lesions (36% faster, p = 0.02). Annual GCIP thinning was 37% faster in those with disability progression during follow-up, and 43% faster in those with disease duration <5 years vs >5 years (p = 0.003). Annual rates of GCIP thinning were highest in patients exhibiting combinations of new gadolinium-enhancing lesions, new T2 lesions, and disease duration <5 years (70% faster in patients with vs without all 3 characteristics,p < 0.001).

Conclusions: MS patients with clinical and/or radiologic nonocular disease activity, particularly early in the disease course, exhibit accelerated GCIP thinning. Our findings suggest that retinal changes in MS reflect global CNS processes, and that OCT-derived GCIP thickness measures may have utility as an outcome measure for assessing neuroprotective agents, particularly in early, active MS.


    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1889556, encodeId=e1241889556e7, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Feb 21 00:41:00 CST 2013, time=2013-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999254, encodeId=ef4a199925417, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Jul 31 22:41:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756021, encodeId=eaae1e560216c, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Wed Aug 28 05:41:00 CST 2013, time=2013-08-28, status=1, ipAttribution=)]
    2013-02-21 jml2009
  2. [GetPortalCommentsPageByObjectIdResponse(id=1889556, encodeId=e1241889556e7, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Feb 21 00:41:00 CST 2013, time=2013-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999254, encodeId=ef4a199925417, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Jul 31 22:41:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756021, encodeId=eaae1e560216c, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Wed Aug 28 05:41:00 CST 2013, time=2013-08-28, status=1, ipAttribution=)]
    2013-07-31 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1889556, encodeId=e1241889556e7, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Feb 21 00:41:00 CST 2013, time=2013-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999254, encodeId=ef4a199925417, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Jul 31 22:41:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756021, encodeId=eaae1e560216c, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Wed Aug 28 05:41:00 CST 2013, time=2013-08-28, status=1, ipAttribution=)]

相关资讯

干扰素β-1a早期治疗可控制MS进展(REFLEXION试验)

       REFLEXION试验3年结果显示,与多发性硬化症(MS)临床确诊后接受治疗的患者相比,首次脱髓鞘事件患者早期皮下注射干扰素β-1a可显著延缓MS进展时间,且最佳剂量为44 μg,3次/w。        该项试验是Ⅲ期双盲REFLEX试验的延长试验,将持

Sci Transl Med:发现一类独特的免疫细胞促进多发性硬化症产生

来自美国国家卫生研究院的研究人员发现一种独特类型的免疫细胞促进多发性硬化症(multiple sclerosis, MS)产生。他们的发现有助于确定研究作为最新药物之一的达利珠单抗(daclizumab)的疗效,而且还可能导致人们开发出一类新药来治疗多发性硬化症和其他自身免疫疾病。在这些疾病中,免疫系统攻击身体自己的组织。正在进行的临床试验已证实达利珠单抗似乎有助于压制多发性硬化症病人的自身免疫反

NEJM:钾通道KIR4.1是多发性硬化症自身免疫反应的靶标

即使是有丰富经验的神经学家,诊断多发性硬化症(MS)也是一项巨大挑战。这种自身免疫性疾病有许多症状,但很少会出现一个统一的临床表现。现在MS中有关免疫反应的新研究发现可能有助于改善这种疾病的诊断。科学家分析MS患者的血液,发现一种攻击细胞膜上特定钾离子通道的抗体。钾离子通道在肌肉和神经细胞传送脉冲过程中发挥了重要作用,而正是上述这些传输过程在MS患者体内受到了抑制。 研究结果发表在最近一期?

JAMA:干扰素β治疗多发性硬化症与患者伤残进展减少无关

芝加哥–据7月18日刊《美国医学会杂志》JAMA上的一项研究披露,在罹患复发-缓解型多发性硬化症(MS)的病人中,用广泛使用于治疗MS的处方药干扰素β进行治疗与患者的较少的伤残进展无关。 加拿大温哥华英属哥伦比亚大学的Afsaneh Shirani, M.D.及其同事开展了一项研究,旨在调查接触干扰素β与复发-缓解型MS的伤残进展之间的关系。这项研究包括了来自英属哥伦比亚的前瞻性收集的数据(19

ECTRIMS 2012:阳光暴露和MS存在负相关关系

       一项新的研究发现,在意大利和挪威居民中,阳光暴露和多发性硬化症(MS)存在显著负相关关系,童年早期居住在意大利和青春期后期居住在挪威之间的负相关性最强。        研究作者 Kjetil Lauvland Bj?rnevik在第28届欧洲多发性硬化症治疗与研究委员会(ECTRIMS)大会上公布了